Skip to the main content

Psychiatria Danubina, Vol. 33 No. suppl 4, 2021.

Conference paper

SELECTIVE SEROTONINE REUPTAKE INHIBITORS (SSRI) USAGE DURING PREGNANCY

Tea Terzić ; University Psychiatric Clinic Ljubljana, Ljubljana, Slovenia
Blanka Kores Plesničar ; University Psychiatric Clinic Ljubljana, Ljubljana, Slovenia

Full text: english pdf 139 Kb

page 1171-1176

downloads: 347

cite

Abstract

Depressive disorders in pregnancy are common and generate concerns regarding their treatment. The effects of untreated
maternal depressive symptoms on preterm birth, low birthweight, fetal growth restriction and postnatal complications are well
known. When left untreated, depressive disorders continue postpartum and have a big impact on the patients' functioning. Selective
serotonine reuptake inhibitors (SSRIs) are the first choice of treatment of depressive disorders. However, there are some concerns
which should be adressed. The aim of this systematic review is to explore the SSRI usage in pregnancy. We studied the latest
literature in the PubMed databases and recommendations from the guidelines. Decision to treat depression in pregnancy should be
taken with careful consideration of many factors. Clinicians should weigh the use of SSRIs during pregnancy against the risk of
untreated depressive disorder.

Keywords

perinatal depression; serotonin; SSRI; pregnancy; breastfeeding

Hrčak ID:

275077

URI

https://hrcak.srce.hr/275077

Publication date:

19.10.2021.

Visits: 621 *